SAM
RDY icon

Sabadell Asset Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Sabadell Asset Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-113,425
Closed -$1.29M – 164
2022
Q1 		$1.29M Hold
113,425
– – 0.22% 92
2021
Q4 		$1.44M Buy
113,425
+55,000
+94% +$693K 0.23% 83
2021
Q3 		$761K Hold
58,425
– – 0.13% 127
2021
Q2 		$859K Buy
+58,425
New +$817K 0.15% 117

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Sabadell Asset Management's RDY Position: Q2 2022 in Review

Sabadell Asset Management sold out of Dr. Reddy's Laboratories (RDY) in Q2 2022, closing a stake of 113,425 shares — an estimated $1.29M sold.

Sabadell Asset Management first reported a position in RDY in Q2 2021 and held it in 4 quarters. The position peaked at $1.44M in Q4 2021. 148 funds tracked by Wall St. Rank hold RDY as of Q2 2022.

  • Sabadell Asset Management reported no remaining Dr. Reddy's Laboratories position as of Q2 2022 after selling out during the quarter.
  • Sabadell Asset Management sold 113,425 Dr. Reddy's Laboratories shares in Q2 2022, an estimated $1.29M.
  • Sabadell Asset Management first reported a position in Dr. Reddy's Laboratories in Q2 2021 and held it in 4 quarters.
  • Sabadell Asset Management's Dr. Reddy's Laboratories position peaked at $1.44M in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2022.

Based on Sabadell Asset Management's 13F filing for Q2 2022, filed 23 Jan 2024.